These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. Iannone F; Gremese E; Atzeni F; Biasi D; Botsios C; Cipriani P; Ferri C; Foschi V; Galeazzi M; Gerli R; Giardina A; Marchesoni A; Salaffi F; Ziglioli T; Lapadula G; J Rheumatol; 2012 Jun; 39(6):1179-84. PubMed ID: 22467933 [TBL] [Abstract][Full Text] [Related]
11. Infections in patients with rheumatoid arthritis treated with biologic agents. Listing J; Strangfeld A; Kary S; Rau R; von Hinueber U; Stoyanova-Scholz M; Gromnica-Ihle E; Antoni C; Herzer P; Kekow J; Schneider M; Zink A Arthritis Rheum; 2005 Nov; 52(11):3403-12. PubMed ID: 16255017 [TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Flouri I; Markatseli TE; Voulgari PV; Boki KA; Papadopoulos I; Settas L; Zisopoulos D; Skopouli FN; Iliopoulos A; Bertsias GK; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P Semin Arthritis Rheum; 2014 Feb; 43(4):447-57. PubMed ID: 24012040 [TBL] [Abstract][Full Text] [Related]
13. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195 [TBL] [Abstract][Full Text] [Related]
14. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M; Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405 [TBL] [Abstract][Full Text] [Related]
15. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. van Dartel SA; Fransen J; Kievit W; Flendrie M; den Broeder AA; Visser H; Hartkamp A; van de Laar MA; van Riel PL Ann Rheum Dis; 2013 Jun; 72(6):895-900. PubMed ID: 22887849 [TBL] [Abstract][Full Text] [Related]
16. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Ollendorf DA; Klingman D; Hazard E; Ray S Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Chatzidionysiou K; Askling J; Eriksson J; Kristensen LE; van Vollenhoven R; Ann Rheum Dis; 2015 May; 74(5):890-6. PubMed ID: 24431398 [TBL] [Abstract][Full Text] [Related]
18. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients. Carter CT; Changolkar AK; Scott McKenzie R J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR; Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821 [TBL] [Abstract][Full Text] [Related]
20. Minimum effective dosages of anti-TNF in rheumatoid arthritis: a cross-sectional study. de la Torre I; Valor L; Nieto JC; Montoro M; Carreño L Reumatol Clin; 2014; 10(2):101-4. PubMed ID: 24280444 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]